Wednesday, September 12, 2018 9:09:23 AM
PD-1 inhibitor market is exploring and projected to reach ~$30B by 2022. Keytruda sales alone is expected to hit over 5B in 2018, compares 3+B sales in 2017. Per Merck's 2Q2018 report, 2Q keytruda sales was 1.67B compared with 1.46B 1Q 2018 sales.
Keytruda sales is on a strong run due to its expanded 5 FDA approvals and it's became ~15% of Merck's total sales and the number may even jump higher with estimated keytruda sales to reach ~10B.
Merck has taken notice, as the ability to increase the efficacy of its PD-1 inhibitor keytruda would mean a huge competitive advantage and cement its head start in the immuno-oncology space. With that, what would be the ONCS's chances to be called from Merck or other big pharma companies?
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM